Financials Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Delayed Nasdaq 03:53:25 2024-05-13 pm EDT 5-day change 1st Jan Change
24 USD +7.29% Intraday chart for Guardant Health, Inc. +26.28% -10.83%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,338 12,884 10,168 2,786 3,283 2,737 - -
Enterprise Value (EV) 1 7,338 11,896 10,370 2,912 3,255 2,990 3,218 3,399
P/E ratio -93 x -49.6 x -25 x -4.24 x -6.32 x -6.96 x -7.66 x -8.7 x
Yield - - - - - - - -
Capitalization / Revenue 34.2 x 44.9 x 27.2 x 6.2 x 5.82 x 4.03 x 3.38 x 2.78 x
EV / Revenue 34.2 x 41.5 x 27.8 x 6.48 x 5.77 x 4.4 x 3.98 x 3.46 x
EV / EBITDA -103 x -140 x -26.7 x -5.84 x -7.46 x -9.82 x -11.3 x -11.7 x
EV / FCF -111 x -84.9 x -36.5 x -7.53 x -9.42 x -10.1 x -12.3 x -14.8 x
FCF Yield -0.9% -1.18% -2.74% -13.3% -10.6% -9.88% -8.12% -6.78%
Price to Book 9.23 x 9.95 x 15.8 x 46.4 x 20.7 x -27.7 x -8.39 x -5.84 x
Nbr of stocks (in thousands) 93,906 99,972 101,656 102,436 121,380 122,369 - -
Reference price 2 78.14 128.9 100.0 27.20 27.05 22.37 22.37 22.37
Announcement Date 2/24/20 2/24/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 214.4 286.7 373.7 449.5 563.9 679.6 808.8 983.1
EBITDA 1 -70.96 -85.18 -388.7 -498.9 -436.3 -304.6 -284.5 -289.6
EBIT 1 -82.37 -255 -411 -544.4 -564.7 -375.2 -352.8 -283.1
Operating Margin -38.42% -88.92% -110% -121.1% -100.14% -55.21% -43.62% -28.8%
Earnings before Tax (EBT) 1 -69.72 -245.9 -384.5 -653.4 -478.8 -382.6 -351.4 -327.6
Net income 1 -75.65 -253.8 -405.7 -654.6 -479.4 -381.1 -349 -322.5
Net margin -35.29% -88.51% -108.57% -145.61% -85.02% -56.07% -43.15% -32.8%
EPS 2 -0.8400 -2.600 -4.000 -6.410 -4.280 -3.216 -2.921 -2.570
Free Cash Flow 1 -65.85 -140.1 -284.1 -386.9 -345.5 -295.3 -261.4 -230.4
FCF margin -30.72% -48.86% -76.02% -86.07% -61.26% -43.45% -32.32% -23.43%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/24/20 2/24/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 108.1 96.1 109.1 117.4 126.9 128.7 137.2 143 155.1 168.5 162.1 169.1 182 186.3 195.6
EBITDA 1 -92.12 -111.6 -120 -122.6 -133.3 -123.4 -108.1 -101.8 -102.9 -88.48 -77.48 -77.09 -78.19 -80.7 -76.69
EBIT 1 -98.21 -123.3 -130.3 -144.6 -146.1 -134.1 -119.6 -113.5 -197.5 -99.68 -97.85 -93.92 -92.3 -99.24 -92.12
Operating Margin -90.84% -128.34% -119.4% -123.16% -115.15% -104.15% -87.22% -79.38% -127.38% -59.16% -60.35% -55.55% -50.72% -53.27% -47.1%
Earnings before Tax (EBT) 1 -72.3 -123.3 -229 -161.9 -139.3 -133.3 -72.28 -85.61 -187.6 -114.6 -101.3 -98.35 -97.67 -98.92 -97.57
Net income 1 -90.91 -123.2 -229.4 -162 -139.9 -133.5 -72.77 -86.1 -187 -115 -97.82 -94.3 -91.53 -94.19 -91.14
Net margin -84.09% -128.23% -210.21% -137.98% -110.28% -103.74% -53.06% -60.2% -120.63% -68.24% -60.33% -55.77% -50.3% -50.56% -46.6%
EPS 2 -0.8900 -1.210 -2.250 -1.580 -1.360 -1.300 -0.6700 -0.7300 -1.580 -0.9400 -0.7989 -0.7685 -0.7468 -0.7678 -0.7443
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/23/22 5/5/22 8/4/22 11/3/22 2/23/23 5/9/23 8/3/23 11/6/23 2/22/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 202 126 - 253 481 661
Net Cash position 1 - 989 - - 28.7 - - -
Leverage (Debt/EBITDA) - - -0.5198 x -0.2529 x - -0.8381 x -1.709 x -2.283 x
Free Cash Flow 1 -65.9 -140 -284 -387 -345 -295 -261 -230
ROE (net income / shareholders' equity) -11.8% -24.2% -41.7% -186% -438% -122% -48.6% -9%
ROA (Net income/ Total Assets) -9.76% -15.7% -18.1% -34.3% -28.2% -15.7% -16.6% -12.4%
Assets 1 775 1,617 2,238 1,907 1,698 2,435 2,065 2,591
Book Value Per Share 2 8.470 13.00 6.340 0.5900 1.300 -0.8100 -2.670 -3.830
Cash Flow per Share 2 -0.5200 -1.070 -2.060 -3.030 -2.900 -1.970 -1.170 0.4400
Capex 1 18.7 36.2 75 77.5 20.5 44.5 51.2 45.8
Capex / Sales 8.73% 12.62% 20.08% 17.23% 3.63% 6.54% 6.33% 4.66%
Announcement Date 2/24/20 2/24/21 2/23/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
22.37 USD
Average target price
37.39 USD
Spread / Average Target
+67.14%
Consensus
  1. Stock Market
  2. Equities
  3. GH Stock
  4. Financials Guardant Health, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW